AU2019339264B2 - Dry powder formulation of caveolin-1 peptides and methods of use thereof - Google Patents

Dry powder formulation of caveolin-1 peptides and methods of use thereof Download PDF

Info

Publication number
AU2019339264B2
AU2019339264B2 AU2019339264A AU2019339264A AU2019339264B2 AU 2019339264 B2 AU2019339264 B2 AU 2019339264B2 AU 2019339264 A AU2019339264 A AU 2019339264A AU 2019339264 A AU2019339264 A AU 2019339264A AU 2019339264 B2 AU2019339264 B2 AU 2019339264B2
Authority
AU
Australia
Prior art keywords
csp7
dry powder
peptide
powder formulation
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019339264A
Other languages
English (en)
Other versions
AU2019339264A1 (en
Inventor
Dale Christensen
John J. Koleng
Sawittree SAHAKIJPIJARN
Alan B. Watts
Robert O. Williams Iii
Yajie ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Rein Therapeutics Inc
Original Assignee
University of Texas System
University of Texas at Austin
Rein Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Rein Therapeutics Inc filed Critical University of Texas System
Publication of AU2019339264A1 publication Critical patent/AU2019339264A1/en
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, LUNG THERAPEUTICS, LLC reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Amend patent request/document other than specification (104) Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, LUNG THERAPEUTICS, INC.
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, REIN THERAPEUTICS, INC. reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Request for Assignment Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, LUNG THERAPEUTICS, LLC
Application granted granted Critical
Publication of AU2019339264B2 publication Critical patent/AU2019339264B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2019339264A 2018-09-10 2019-09-10 Dry powder formulation of caveolin-1 peptides and methods of use thereof Active AU2019339264B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729010P 2018-09-10 2018-09-10
US62/729,010 2018-09-10
PCT/US2019/050349 WO2020055824A1 (en) 2018-09-10 2019-09-10 Dry powder formulation of caveolin-1 peptides and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2019339264A1 AU2019339264A1 (en) 2021-03-11
AU2019339264B2 true AU2019339264B2 (en) 2025-05-29

Family

ID=69778150

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019339264A Active AU2019339264B2 (en) 2018-09-10 2019-09-10 Dry powder formulation of caveolin-1 peptides and methods of use thereof

Country Status (9)

Country Link
US (3) US12280088B2 (https=)
EP (1) EP3849581A4 (https=)
JP (2) JP7514840B2 (https=)
KR (1) KR20210057127A (https=)
CN (2) CN112996530B (https=)
AU (1) AU2019339264B2 (https=)
BR (1) BR112021004420A2 (https=)
CA (1) CA3109982A1 (https=)
WO (1) WO2020055824A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110201144B (zh) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
US20240082342A1 (en) * 2018-11-21 2024-03-14 Board Of Regents, The University Of Texas System Peptide therapeutics for increasing lung cell viability
US20220370544A1 (en) * 2018-11-21 2022-11-24 Board Of Regents, The University Of Texas System Peptide therapeutics for acute and chronic airway and alveolar diseases
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
EP4138791A1 (en) * 2020-04-20 2023-03-01 Board of Regents, The University of Texas System Biologically active dry powder compositions and method of their manufacture and use
US20230159608A1 (en) * 2020-04-21 2023-05-25 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and uses thereof
US20230226149A1 (en) * 2020-06-19 2023-07-20 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
US20250041383A1 (en) * 2021-06-17 2025-02-06 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of post-acute covid-19
US20250262273A1 (en) * 2021-10-22 2025-08-21 Rein Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of chronic kidney disease
EP4719450A2 (en) * 2023-05-30 2026-04-08 Rein Therapeutics, Inc. Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof
CN121695995A (zh) * 2024-09-18 2026-03-20 深圳翰宇药业股份有限公司 一种多肽药物的粉碎方法
CN119661656A (zh) * 2024-11-20 2025-03-21 华中科技大学同济医学院附属梨园医院 一种靶向拮抗pCAV1的多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
US20020077283A1 (en) * 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
EP1501479A1 (en) 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
EP2074142A4 (en) * 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
BR112015022831A2 (pt) 2013-03-13 2017-08-22 Forest Laboratories Holdings Ltd Composições farmacêuticas micronizadas
CN110201144B (zh) * 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
WO2015080980A2 (en) 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
EP3262856B1 (en) * 2015-02-27 2020-02-19 PCMS Holdings, Inc. Systems and methods for secure roll-over of device ownership

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTHIAS SCHMITZ: "Effect of cavtratin, a caveolin-1 scaffolding domain peptide, on oligodendroglial signaling cascades", CELL MOL NEUROBIOL., vol. 31, no. 7, pages 991 - 997, XP019955941, DOI: 10.1007/s10571-011-9694-1 *

Also Published As

Publication number Publication date
CN112996530B (zh) 2025-06-03
US20210260150A1 (en) 2021-08-26
JP2024114982A (ja) 2024-08-23
JP7514840B2 (ja) 2024-07-11
WO2020055824A1 (en) 2020-03-19
CA3109982A1 (en) 2020-03-19
US20240269225A1 (en) 2024-08-15
CN120459067A (zh) 2025-08-12
AU2019339264A1 (en) 2021-03-11
BR112021004420A2 (pt) 2021-06-01
CN112996530A (zh) 2021-06-18
US20250302910A1 (en) 2025-10-02
US12280088B2 (en) 2025-04-22
EP3849581A1 (en) 2021-07-21
WO2020055824A8 (en) 2020-05-14
EP3849581A4 (en) 2022-07-06
JP2022500500A (ja) 2022-01-04
KR20210057127A (ko) 2021-05-20
US12280089B2 (en) 2025-04-22

Similar Documents

Publication Publication Date Title
US12280089B2 (en) Dry powder formulation of caveolin-1 peptides and methods of use thereof
JP7737492B2 (ja) Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
EP4168031A2 (en) Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
US20220160814A1 (en) Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
US20250262273A1 (en) Modified caveolin-1 peptides for the treatment of chronic kidney disease
US20250041383A1 (en) Modified caveolin-1 peptides for the treatment of post-acute covid-19

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Free format text: FORMER NAME(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; LUNG THERAPEUTICS, INC.

Owner name: LUNG THERAPEUTICS, LLC

Free format text: FORMER NAME(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; LUNG THERAPEUTICS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Free format text: FORMER APPLICANT(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; LUNG THERAPEUTICS, LLC

Owner name: REIN THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; LUNG THERAPEUTICS, LLC

FGA Letters patent sealed or granted (standard patent)